Force") has issued this focused update to revise guideline recommendations on the basis of recently published data. This update is not based on a complete literature review from the date of previous guideline publications, but it has been subject to rigorous, multilevel review and approval, similar to the full guidelines. For specific focused update criteria and additional methodological details, please see the ACC/AHA guideline methodology manual (1) .
Modernization
In response to published reports from the Institute of Medicine (2, 3) and ACC/AHA mandates (4-7), processes have changed leading to adoption of a "knowledge byte" format. This entails delineation of recommendations addressing specific clinical questions, followed by concise text, with hyperlinks to supportive evidence. This approach better accommodates time constraints on busy clinicians, facilitates easier access to recommendations via electronic search engines and other evolving technology (e.g., smart phone apps), and supports the evolution of guidelines as "living documents" that can be dynamically updated as needed.
Intended Use
Practice guidelines provide recommendations applicable to patients with or at risk of developing cardiovascular disease. The focus is on medical practice in the United States, but guidelines developed in collaboration with other organizations may have a broader target. Although guidelines may inform regulatory or payer decisions, they are intended to improve quality of care in the interest of patients.
Class of Recommendation and Level of Evidence
The Class of Recommendation (COR) and Level of Evidence (LOE) are derived independently of one another according to established criteria. The COR indicates the strength of recommendation, encompassing the estimated magnitude and certainty of benefit of a clinical action in proportion to risk. The LOE rates the quality of scientific evidence supporting the intervention on the basis of the type, quantity, and consistency of data from clinical trials and other sources (Table 1) (1, 7, 8) .
Relationships With Industry and Other Entities
The ACC and AHA sponsor the guidelines without commercial support, and members volunteer their time. The Task Force zealously avoids actual, potential, or perceived conflicts of interest that might arise through relationships with industry or other entities (RWI). All Guideline Writing Committee (GWC) members and reviewers are required to disclose current industry relationships or personal interests from 12 months before initiation of the writing effort. Management of RWI involves selecting a balanced GWC and assuring that the chair and a majority of committee members have no relevant RWI (Appendixes 1 and 2). Members are restricted with regard to writing or voting on sections to which their RWI apply. For transparency, members' comprehensive disclosure information is available online (http://jaccjacc.acc.org/Clinical_Document/2015_Focused_Update_on_Primary_PCI_in_STEMI_Comprehensive _RWI_Table.pdf). Comprehensive disclosure information for the Task Force is available at http://www.acc.org/guidelines/about-guidelines-and-clinical-documents/guidelines-and-documents-task-forces.
The Task Force strives to avoid bias by selecting experts from a broad array of backgrounds representing different geographic regions, sexes, ethnicities, intellectual perspectives/biases, and scopes of clinical practice, and by inviting organizations and professional societies with related interests and expertise to participate as partners or collaborators.
Related Issues
For additional information pertaining to the methodology for grading evidence, assessment of benefit and harm, shared decision making between the patient and clinician, structure of evidence tables and summaries, standardized terminology for articulating recommendations, organizational involvement, peer review, and policies for periodic assessment and updating of guideline documents, we encourage readers to consult the ACC/AHA guideline methodology manual (1) .
The recommendations in this focused update represent the official policy of the ACC and AHA until superseded by published addenda, statements of clarification, focused updates, or revised full-text guidelines. To ensure that guidelines remain current, new data are reviewed biannually to determine whether recommendations should be modified. In general, full revisions are posted in 5-year cycles (1) . 
Introduction
The scope of this focused update is limited to considerations relevant to multivessel percutaneous coronary intervention (PCI) and thrombus aspiration in patients with ST-elevation myocardial infarction (STEMI) undergoing primary PCI.
Methodology and Evidence Review
Clinical trials presented at the major cardiology organizations' 2013 to 2015 Consult the full-text versions of the 2011 PCI and 2013 STEMI guidelines (9,10) for recommendations in clinical areas not addressed in the focused update. The individual recommendations in this focused update will be incorporated into future revisions or updates of the full-text guidelines. 
Organization of the GWC

Review and Approval
This document was reviewed predominantly by the prior reviewers from the respective 2011 and 2013 guidelines. 
Culprit Artery-Only Versus Multivessel PCI
Class IIb
PCI of a noninfarct artery may be considered in selected patients with STEMI and multivessel disease who are hemodynamically stable, either at the time of primary PCI or as a planned staged procedure (11) (12) (13) (14) (15) (16) (17) (18) (19) (20) (21) (22) (23) (24) .
(Level of Evidence: B-R)
Modified recommendation (changed class from "III: Harm" to "IIb" and expanded time frame in which multivessel PCI could be performed).
PCI indicates percutaneous coronary intervention; and STEMI, ST-elevation myocardial infarction.
Approximately 50% of patients with STEMI have multivessel disease (25, 26) . PCI options for patients with STEMI and multivessel disease include: 1) culprit artery-only primary PCI, with PCI of nonculprit arteries only for spontaneous ischemia or intermediate-or high-risk findings on predischarge noninvasive testing; 2) multivessel PCI at the time of primary PCI; or 3) culprit artery-only primary PCI followed by staged PCI of nonculprit arteries. Observational studies, randomized controlled trials (RCTs), and meta-analyses comparing culprit artery-only PCI with multivessel PCI have reported conflicting results (11, 12, (14) (15) (16) (17) (18) (19) (20) (21) (22) (23) (24) 27, 28) , likely because of differing inclusion criteria, study protocols, timing of multivessel PCI, statistical heterogeneity, and variable endpoints (Data Supplement).
Previous clinical practice guidelines recommended against PCI of nonculprit artery stenoses at the time of primary PCI in hemodynamically stable patients with STEMI (9,10). Planning for routine, staged PCI of noninfarct artery stenoses on the basis of the initial angiographic findings was not addressed in these previous guidelines, and noninfarct artery PCI was considered only in the limited context of spontaneous ischemia or highrisk findings on predischarge noninvasive testing. The earlier recommendations were based in part on safety concerns, which included increased risks for procedural complications, longer procedural time, contrast nephropathy, and stent thrombosis in a prothrombotic and proinflammatory state (9, 10) , and in part on the findings from many observational studies and meta-analyses of trends toward or statistically significant worse outcomes in those who underwent multivessel primary PCI (12) (13) (14) (15) (16) (21) (22) (23) On the basis of these findings (17, 18, 24, 27) , the prior Class III (Harm) recommendation with regard to multivessel primary PCI in hemodynamically stable patients with STEMI has been upgraded and modified to a Although several observational studies (19, 20) and a network meta-analysis (13) have suggested that multivessel staged PCI may be associated with better outcome than multivessel primary PCI, there are insufficient observational data and no randomized data at this time to inform a recommendation with regard to the optimal timing of nonculprit vessel PCI. Additional trial data that will help further clarify this issue are awaited. Issues related to the optimal method of evaluating nonculprit lesions (e.g., percent diameter stenosis, fractional flow reserve) are beyond the scope of this focused update. 
2011/2013 Recommendation 2015 Focused Update Recommendations Comments
Class IIa
Manual aspiration thrombectomy is reasonable for patients undergoing primary PCI (29) (30) (31) (32) . (Level of Evidence: B)
Class IIb
The usefulness of selective and bailout aspiration thrombectomy in patients undergoing primary PCI is not well established (33) (34) (35) (36) (37) . (Level of Evidence: C-LD)
Class III: No Benefit
Routine aspiration thrombectomy before primary PCI is not useful (33) (34) (35) (36) (37) .
(Level of Evidence: A)
Modified recommendation (Class changed from "IIa" to "IIb" for selective and bailout aspiration thrombectomy before PCI).
New recommendation ("Class III:
No Benefit" added for routine aspiration thrombectomy before PCI).
PCI indicates percutaneous coronary intervention; and LD, limited data.
The 2011 PCI and 2013 STEMI guidelines' (9,10) Class IIa recommendation for aspiration thrombectomy before primary PCI was based on the results of 2 RCTs (29,31,32) and 1 meta-analysis (30) and was driven in large measure by the results of TAPAS (Thrombus Aspiration During Primary Percutaneous Coronary Intervention in Acute Myocardial Infarction Study), a single-center study that randomized 1,071 patients with STEMI to aspiration thrombectomy before primary PCI or primary PCI only (29, 32) . Three multicenter trials, 2 of which enrolled significantly more patients than prior aspiration thrombectomy trials, have prompted reevaluation of this
recommendation. In the INFUSE-AMI (Intracoronary Abciximab and Aspiration Thrombectomy in Patients With
Large Anterior Myocardial Infarction) trial (37) of 452 patients with anterior STEMI due to proximal or mid-left anterior descending occlusion, infarct size was not reduced by aspiration thrombectomy before primary PCI. The TASTE (Thrombus Aspiration During ST-Segment Elevation Myocardial Infarction) trial (n=7,244) incorporated a unique design that allowed randomization within an existing national registry, resulting in enrollment of a remarkably high proportion of eligible patients (34, 36) . No significant 30-day or 1-year differences were found between the group that received aspiration thrombectomy before primary PCI and the group that received primary PCI only with regard to death, reinfarction, stent thrombosis, target lesion revascularization, or a composite of major adverse cardiac events. The TOTAL (Trial of Routine Aspiration Thrombectomy With PCI Versus PCI Alone in Patients With STEMI) trial randomized 10,732 patients with STEMI to aspiration thrombectomy before primary PCI or primary PCI only (35) . Bailout thrombectomy was performed in 7.1% of the primary PCI-only group, whereas the rate of crossover from aspiration thrombectomy before primary PCI to primary PCI only was 4.6%. There were no differences between the 2 treatment groups, either in the primary composite endpoint of revascularization. There was a small but statistically significant increase in the rate of stroke in the aspiration thrombectomy group. An updated meta-analysis that included these 3 trials among a total of 17 trials (n=20,960)
found no significant reduction in death, reinfarction, or stent thrombosis with routine aspiration thrombectomy.
Aspiration thrombectomy was associated with a small but nonsignificant increase in the risk of stroke (33) .
Several previous studies have found that higher thrombus burden in patients with STEMI is independently associated with higher risks of distal embolization, no-reflow phenomenon, transmural myocardial necrosis, major adverse cardiac events, stent thrombosis, and death (38) (39) (40) (41) (42) . However, subgroup analyses from the TASTE and TOTAL trials did not suggest relative benefit from aspiration thrombectomy before primary PCI in patients with higher thrombus burden or in patients with initial Thrombolysis in Myocardial Infarction (TIMI) flow grade 0-1 or left anterior descending artery / anterior infarction (34, 35) .
On the basis of the results of these studies, the prior Class IIa recommendation for aspiration thrombectomy has been changed. Routine aspiration thrombectomy before primary PCI is now not recommended (Class III: No Benefit, LOE A). There are insufficient data to assess the potential benefit of a strategy of selective or bailout aspiration thrombectomy (Class IIb, LOE C-LD). "Bailout" aspiration thrombectomy is defined as thrombectomy that was initially unplanned but was later used during the procedure because of unsatisfactory initial result or procedural complication, analogous to the definition of "bailout" glycoprotein IIb/IIIa use.
It should be noted that the preceding recommendations and text apply only to aspiration thrombectomy;
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